Dyax (DYAX) -14% AH after declaring it will discontinue its Phase 2 trial for a drug meant to...

|About: Dyax Corp. (DYAX)|By:, SA News Editor

Dyax (DYAX) -14% AH after declaring it will discontinue its Phase 2 trial for a drug meant to treat angiodema. Dyax says data from 72 patients taking part in the trials failed to produce a "statistically significant" difference in results for those taking its drug relative to those taking a placebo. Nonetheless, the company remains committed to broader angiodema drug development.